职称:青年研究员
电子邮箱:yanyong_xu@fudan.edu.cn
办公地点:东一号楼208室
研究方向
学术报告
重要学术贡献
荣誉与获奖
科研成果
方向一 糖脂代谢紊乱与代谢性疾病分子机制研究及药物干预
China Obesity Congress ,“The Dual Role of HNF4a in NAFLD and Obesity” ,特邀报告 July 30-31, 2021
复旦大学代谢沙龙华山内分泌会议,“Transcriptional regulation of hepatic lipid metabolism and metabolic disorders”,特邀报告July 3,2021
The 3rd CALS Annual Symposium,“Hepatocyte ATF3 protects against diet-induced nonalcoholic fatty liver disease by regulating the HNF4α and bile acid signaling ”,主题报告October 30-31, 2020
ATVB 学术会议“Mir34a is a Key Regulator Linking Liver and Macrophages to Atherosclerosis”,主题报告May 5-7, 2020
本人主要从事代谢性疾病(非酒精性脂肪肝病-NAFLD、动脉粥样硬化-Atheroscerosis/As)糖脂代谢紊乱分子机制研究,力图探寻新的调控糖脂代谢的转录因子、核受体、非编码小RNA 、信号分子/酶,致力于发现代谢性疾病的致病新通路并转化临床干预疾病的研究。近5年已以第一作者或共同通讯作者发表SCI论文12篇,影响因子累计98.449(第一作者或共同通讯作者论文)。其中1区论文7篇,2区论文1篇。包括代谢领域重要杂志Nature Metabolism, Hepatology, Molecular Therapy, Diabetes, Molecular Metabolism等。研究成果曾获中国脂质与脂蛋白学术会议青年论坛一等奖、湖北省生物化学与分子生物学学术论文二等奖、湖北省自然科学优秀学术论文三等奖等奖项。此外,申请者还担任多个代谢领域知名期刊的审稿人,如J Lipid Res、Front Cell Dev Biol、Atherosclerosis 等杂志。
湖北省自然科学优秀学术论文三等奖,湖北省,中国,2016年
中国脂质与脂蛋白学术会议第十二届青年论坛一等奖,中国,2015年
湖北省生物化学与分子生物学学术论文竞赛二等奖,湖北省,中国,2014年
发表论文:
# 第一作者或共同第一作者;*通讯作者
Yanyong Xu#*, Shuwei Hu#, Kavita Jadhav, Yingdong Zhu, Xiaoli Pan, Liya Yin, Yanqiao Zhang*. Hepatocytic Activating Transcription Factor 3 Protects Against Steatohepatitis Via Hepatocyte Nuclear Factor 4α. Diabetes, 2021. online. (correspondence)
Yanyong Xu#, Yingdong Zhu#, Shuwei Hu, Xiaoli Pan, Liya Yin, and Yanqiao Zhang*. Hepatocyte miR-34a is a key regulator of the development and progression of non-alcoholic fatty liver disease. Molecular Metabolism, 2021.Apr 28;51:101244. doi: 10.1016/j.molmet.2021.101244. Online ahead of print.
Yanyong Xu #, Yuanyuan Li #, Kavita Jadhav #, Xiaoli Pan, Yingdong Zhu, Shuwei Hu, Shaoru Chen, Liuying Chen, Yong Tang, Ling Yang, David Q.-H. Wang, Liya Yin, Yanqiao Zhang*. Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism. Nature Metabolism, 2021; 3:59-74. (Nature 子刊)
Yanyong Xu #, Yingdong Zhu, Shuwei Hu, Yang Xu, Diane Stroup, Xiaoli Pan, Fathima Cassim Bawa, Shaoru Chen, Raja Gopoju, Liya Yin, and Yanqiao Zhang*. Hepatocyte Nuclear Factor 4α prevents the steatosis-to-NASH progression by regulating the P53 and bile acid signaling. Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604. Online ahead of print.
Yanyong Xu #, Yang Xu #, Yingdong Zhu#, Huihui Sun, Cody Juguilon, Feng Li, Daping Fan, Liya Yin, and Yanqiao Zhang*. Macrophage MiR-34a Is A Key Regulator of Cholesterol Efflux and Atherosclerosis. Molecular Therapy, 2020 ;28:202-216. (Cell 子刊)
Yanyong Xu#, Xiaoli Pan#, Shuwei Hu#, Yingdong Zhu, Fathima Cassim Bawa, Yuanyuan Li, Liya Yin, and Yanqiao Zhang*. Hepatocyte-Specific Expression of Human Carboxylesterase 2 Attenuates Non-alcoholic Steatohepatitis in Mice. Am J Physiol Gastrointest Liver Physiol. 2021 ;320(2):G166-G174.
Yanyong Xu #, Yingdong Zhu, Fathima Cassim Bawa, Shuwei Hu, Xiaoli Pan, Liya Yin, and Yanqiao Zhang*. Hepatocyte-specific Expression of Human Carboxylesterase 1 Attenuates Diet-induced Steatohepatitis and Hyperlipidemia. Hepatology communications, 2020 ;4:527-539.
Yanyong Xu #, Feifei Li#, Xiaojie Zhao, Chenkun Tan, Binyi Wang, Yiyong Chen, Jia Cao, Dongfang Wu and Hong Yu*. Methionine sulfoxide reductase A attenuates atherosclerosis via repairing dysfunctional HDL in scavenger receptor class B type I deficient mice. The FASEB Journal, 2020 ;34:3805-3819.
Yanyong Xu #, Yingdong Zhu, Kavita Jadhav, Yuanyuan Li, Huihui Sun, Liya Yin, Takhar Kasumov, Xiaoli Chen, and Yanqiao Zhang*. Lipocalin-2 Protects Against Diet-induced Non-alcoholic Fatty Liver Disease by Targeting Hepatocytes. Hepatology Communications, 2019;3:763-775.
Yanyong Xu #, Hongmei Liu #, Mengting Liu, Feifei Li, Liangchen Liu, Fen Du, Daping Fan, Hong Yu*. A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice. American Journal of Translational Research, 2016; 8:3482-3492.